Skip to main content
SpringerLink
Log in

Cardiovascular Issues and Renal Disease

  • Chapter
  • First Online:
Evidence-Based Cardiology Consult

  • 1904 Accesses

Abstract

The increasing prevalence of both chronic kidney disease (CKD) and cardiovascular disease requires a better understanding by physicians in practice. The regular emergence of newer data continues to support the unique and complex interaction between the kidney and the heart. CKD has been associated with increased risk of in-hospital death and major bleeding in patients with acute coronary syndromes (ACS). A higher level of risk stratification is required for these patients. Contrast-induced acute kidney injury requires a comprehensive management strategy in patients receiving percutaneous therapy for ACS. Patients with CKD are susceptible to cardiorenal syndromes which complicate bidirectional organ dysfunction and are particularly challenging to manage. Treatment and prevention methods continue to be adjusted to better incorporate the new improvements and recommendations in everyday clinical practice. In light of newer guidelines, nephrologists and cardiologists must work in tandem for better diagnosis and management. Imaging and laboratory diagnostic testing are now being utilized with better insight pertinent to each disease process. Medications and dosages must be adjusted with respect to the underlying physiology and pathophysiology of the two entities. Certain cardiovascular diseases (VHD, arrhythmias, PAD) are being looked at from a different angle, hoping for improvements in therapies. Further advances in the understanding of pathophysiological mechanisms at work in patients with CKD will continue to lead to new diagnostic and therapeutic targets in this high-risk population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 209.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Centers for Disease Control and Prevention (CDC). National chronic kidney disease fact sheet: general information and national estimates on chronic kidney disease in the United States, 2010. Atlanta: U.S. Department of Health and Human Services (HHS), CDC; 2010.

    Google Scholar 

  2. USRDS 2010 Annual Data Report. United States renal data system. Website: www.usrds.org/adr.htm. Accessed 8 Nov 2010. (The USRDS end-stage renal disease incident and prevalent quarterly update is available at: www.usrds.org/qtr/default.html).

  3. Heron MP, Hoyert DL, Murphy SL, Xu JQ, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Nat Vital Stat Rep;57(14). Hyattsville: National Center for Health Statistics; 2009:1–2.

    Google Scholar 

  4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.

    PubMed  CAS  Google Scholar 

  5. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737–45.

    PubMed  CAS  Google Scholar 

  6. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154.

    PubMed  Google Scholar 

  7. Shlipak MG, Liu HH, Schiller NB, Whooley MA. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. J Am Soc Nephrol. 2003;14(12):3233.

    PubMed  Google Scholar 

  8. Hanna EB, Chen AY, Roe MT, Wiviott SD, Fox CS, Saucedo JF. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2011;4(9):1002–8.

    PubMed  Google Scholar 

  9. De Servi S, Guastoni C, Mariani M, Poli A, D’Urbano M, Poletti F, Seveso G. Chronic renal failure in acute coronary syndromes. G Ital Cardiol (Rome). 2006;7(4 Suppl 1):30S–5.

    Google Scholar 

  10. McCullough PA, Nowak RM, Foreback C, Tokarski G, Tomlanovich MC, Khoury N, Weaver WD, Sandberg KR, McCord J. Emergency evaluation of chest pain in patients with advanced kidney disease. Arch Intern Med. 2002;162(21):2464–8.

    PubMed  Google Scholar 

  11. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108–16.

    PubMed  CAS  Google Scholar 

  12. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377–84.

    PubMed  CAS  Google Scholar 

  13. Kirtane AJ, Piazza G, Murphy SA, Budiu D, Morrow DA, Cohen DJ, Peterson E, Lakkis N, Herrmann HC, Palabrica TM, Gibson CM. Correlates of bleeding events among moderate to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006;47:2374–9.

    PubMed  CAS  Google Scholar 

  14. Diesel W, Emms M, Knight BK, et al. Morphological features of the myopathy associated with chronic renal failure. Am J Kid Dis. 1993;22:677–84.

    PubMed  CAS  Google Scholar 

  15. Antman EM, Grudzien C, Mitchell RN, Sacks DB. Detection of unsuspected myocardial necrosis by rapid bedside assay for cardiac troponin T. Am Heart J. 1997;133:596–8.

    PubMed  CAS  Google Scholar 

  16. Diris JH, Hackeng CM, Kooman JP, et al. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation. 2004;109:23.

    PubMed  CAS  Google Scholar 

  17. Fredericks S, Chang R, Gregson H, et al. Circulating cardiac troponin T in patients before and after renal transplantation. Clin Chim Acta. 2001;310:199–203.

    PubMed  CAS  Google Scholar 

  18. Aronow WS, Ahn C, Mercando AD, Epstein S. Prevalence of coronary artery disease, complex ventricular arrhythmias, and silent myocardial ischemia and incidence of new coronary artery events in older persons with chronic renal insufficiency and with normal renal function. Am J Cardiol. 2000;86:1142–3.

    PubMed  CAS  Google Scholar 

  19. Zawada ET, Stinson JB, Done G. New perspectives on coronary artery disease in hemodialysis patients. South Med J. 1982;75:694–6.

    PubMed  Google Scholar 

  20. Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol. 2002;40:2065–71.

    PubMed  CAS  Google Scholar 

  21. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin-I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342.

    PubMed  CAS  Google Scholar 

  22. Martin GS, Becker BN, Schulman G. Cardiac troponin-I accurately predicts myocardial injury in renal failure. Nephrol Dial Transplant. 1998;13:1709–12.

    PubMed  CAS  Google Scholar 

  23. Wayand D, Baum H, Schatzle G, Scharf J, Neumeier D. Cardiac troponin T and I in end-stage renal failure. Clin Chem. 2000;46:1345–50.

    PubMed  CAS  Google Scholar 

  24. Sanofi U.S. Medication Guide Revised Dec 2011 Distributed by: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership Bridgewater. Available http://products.sanofi.us/plavix/plavix.html#section-11.5.

  25. Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J. 2011;32(23):2933–44.

    PubMed  CAS  Google Scholar 

  26. Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, Lopez-Sendon J, Laufenberg CV, Klutman M, Gowda N, Gulba D. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J. 2005;26:2285–93.

    PubMed  Google Scholar 

  27. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction – 2002 summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation. 2002;106:1893–900.

    PubMed  Google Scholar 

  28. Paoletti E, Cassottana P, Bellino D, et al. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis. 2002;40(4):728–36.

    PubMed  CAS  Google Scholar 

  29. Shibasaki Y, Masaki H, Nishiue T, et al. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron. 2002;90(3):256–61.

    PubMed  CAS  Google Scholar 

  30. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438–44.

    PubMed  CAS  Google Scholar 

  31. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol. 2006;98:71i–6.

    PubMed  CAS  Google Scholar 

  32. Investigators ACT. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT). Circulation. 2011;124:1250–9.

    Google Scholar 

  33. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024–31.

    PubMed  CAS  Google Scholar 

  34. Tonelli M, Moyé L, Sacks FM, Kiberd B, Curhan G. Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138(2):98–104.

    PubMed  CAS  Google Scholar 

  35. Freeman RV, Mehta RH, Al Badr W, et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol. 2003;41(5):718–24.

    PubMed  CAS  Google Scholar 

  36. Jeremias A, Bhatt DL, Chew DP, et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol. 2002;89(10):1209–11.

    PubMed  CAS  Google Scholar 

  37. Frilling B, Zahn R, Fraiture B, et al. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and with renal insufficiency treated with abciximab. Am J Cardiol. 2002;89(4):450–2.

    PubMed  CAS  Google Scholar 

  38. Best PJ, Lennon R, Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J. 2003;146(2):345–50.

    PubMed  CAS  Google Scholar 

  39. Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non-ST segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:670S–707.

    PubMed  CAS  Google Scholar 

  40. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol. 2007;50(18):1742–51.

    PubMed  CAS  Google Scholar 

  41. Keeley EC, Kadakia R, Soman S, Borzak S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol. 2003;92(5):509–14.

    PubMed  Google Scholar 

  42. Chan MY, Becker RC, Sim LL, et al. Reperfusion strategy and mortality in ST-elevation myocardial infarction among patients with and without impaired renal function. Ann Acad Med Singapore. 2010;39:179–84.

    PubMed  Google Scholar 

  43. Charytan DM, Wallentin L, Lagerqvist B, et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol. 2009;4:1032–43.

    PubMed  Google Scholar 

  44. Szummer K, Lundman P, Jacobson SH, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation. 2009;120:851–8.

    PubMed  CAS  Google Scholar 

  45. Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). Am Heart J. 2005;149:512–9.

    PubMed  Google Scholar 

  46. Szczech LA, Reddan DN, Owen WF, et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int. 2001;60:292–9.

    PubMed  CAS  Google Scholar 

  47. Contrast-Induced Nephropathy Renu Bansal, Chief Editor: Vecihi Batuman. E-Medicine (www.emedicine.com) Updated 29 July 2011. Available at: http://emedicine.medscape.com/article/246751-overview.

  48. Ilkhanoff L, Carver J. Contrast-induced nephropathy and cardiac catheterization: evidence in support of using the iso-osmolar contrast agent. 2005. Available at: http://www.invasivecardiology.com/article/3990.

  49. Friedewald VE, Goldfarb S, Laskey WK, et al. The editor’s roundtable: contrast-induced nephropathy. Am J Cardiol. 2007;100(3):544–51.

    PubMed  Google Scholar 

  50. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxicity in high-risk patients study of iso-osmolar and low-osmolar non-ionic contrast media study investigators. N Engl J Med. 2003;348(6):491–9.

    PubMed  CAS  Google Scholar 

  51. Davidson CJ, Laskey WK, Hermiller JB, Harrison JK, Matthai Jr W, Vlietstra RE, et al. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation. 2000;101(18):2172–7.

    PubMed  CAS  Google Scholar 

  52. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17(9):2359–62.

    PubMed  Google Scholar 

  53. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007;56(10):3433–41.

    PubMed  Google Scholar 

  54. Cowper SE, Kuo PH, Bucala R. Nephrogenic systemic fibrosis and gadolinium exposure: association and lessons for idiopathic fibrosing disorders. Arthritis Rheum. 2007;56(10):3173–5.

    PubMed  CAS  Google Scholar 

  55. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med. 2006;130(2):209–12.

    PubMed  Google Scholar 

  56. Broome DR, Cottrell AC, Kanal E. Response to “will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?”. AJR Am J Roentgenol. 2007;189:W234–5.

    PubMed  Google Scholar 

  57. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2005;290:F262–72.

    Google Scholar 

  58. Vaziri ND, Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int. 2006;10:1–7.

    PubMed  Google Scholar 

  59. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant. 1999;14:1462–6.

    PubMed  CAS  Google Scholar 

  60. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51(25):2375–84. ISSN:0735-1097/08jacc.2008.03.02.

    Google Scholar 

  61. Jardine AG, Holdaas H, Fellstrom B, et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT study. Am J Transplant. 2004;4:988–95.

    PubMed  CAS  Google Scholar 

  62. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. Veterans’ Affairs High-Density Lipoprotein Intervention Trial Investigators. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int. 2004;66:1123–30.

    PubMed  CAS  Google Scholar 

  63. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996;49:1428–34.

    PubMed  CAS  Google Scholar 

  64. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61:297–304.

    PubMed  CAS  Google Scholar 

  65. Andreucci VE, Fissell RB, Bragg-Gresham JL, et al. Dialysis out-comes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis. 2004;44:61–7.

    PubMed  Google Scholar 

  66. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.

    PubMed  CAS  Google Scholar 

  67. Baigent C, Landray MJ, Reith C, behalf of the SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet. 2011;377(9784):2181–92.

    PubMed  CAS  Google Scholar 

  68. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S142–56.

    PubMed  CAS  Google Scholar 

  69. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–82.

    PubMed  CAS  Google Scholar 

  70. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887–93.

    PubMed  Google Scholar 

  71. Bolton K, Coresh J, Culleton B et al. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. National Kidney Foundation. Available at: www.kidney.org/professionals/kdoqi/guidelines.cfm.

  72. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease. Am J Kidney Dis. 2003;41 Suppl 3:S1–237.

    Google Scholar 

  73. Corsini A, Holdass H. Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Ren Fail. 2005;27:259–73.

    PubMed  CAS  Google Scholar 

  74. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Am J Cardiol. 1994;73:3D.

    PubMed  CAS  Google Scholar 

  75. Nishizawa Y, Shoji T, Nishitani H, et al. Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: effect of a fibric acid, clinofibrate. Kidney Int. 1993;44:1352.

    PubMed  CAS  Google Scholar 

  76. Jacobson TA, Zimmerman FH. Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens. 2006;8:35–41.

    CAS  Google Scholar 

  77. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99:3C–18.

    PubMed  CAS  Google Scholar 

  78. Health Resources and Services Administration, U.S. Department of Health & Human Services. Organ Procurement and Transplant Network Database. Available at: http://optn.transplant.hrsa.gov/. Accessed 21 Jan 2009.

  79. U.S. Renal Data System: USRDS. 2008 annual data report. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008. Atlas of ESRD, transplantation, Figure 7.31. Available at: http://www.usrds.org/2008/view/esrd_07.as.

  80. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57:307–13.

    PubMed  CAS  Google Scholar 

  81. Fishbane S. Cardiovascular risk evaluation before kidney transplantation. Am Soc Nephrol. 2005;16:843–5.

    Google Scholar 

  82. Ramos EL, Kasiske BL, Alexander SR, Danovitch GM, Harmon WE, Kahana L, Kiresuk TJ, Neylan JF. The evaluation of candidates for renal transplantation: the current practice of U.S. transplant centers. Transplantation. 1994;57:490–7.

    PubMed  CAS  Google Scholar 

  83. Ryckelynck JP, et al. Peritoneal UF and treatment-resistant heart failure. Nephrol Dial Transplant. 1998;13:56–9.

    PubMed  Google Scholar 

  84. United States Renal Data System Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States 2007 Annual Data Report volume ii. Available at: http://www.usrds.org/2007/ref_07.pdf.

  85. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527.

    PubMed  Google Scholar 

  86. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions-insights from the ESCAPE trial. J Am Coll Cardiol. 2007;51:1268–74.

    Google Scholar 

  87. Greenberg A, et al. Primer on kidney diseases. 5th ed. Philadelphia: Saunders/Elsevier; 2009.

    Google Scholar 

  88. Goel S, et al. Classification and pathophysiology of cardiorenal syndrome. ASN Kidney News. 2010; p. 9.

    Google Scholar 

  89. Yazigi F, et al. Which marker should we use to assess acute renal injury? http://biomarkers.cardiosource.org/Hot-Topics/2011/04/Which-marker-should-we-use-to-assess-acute-renal-injury.aspx.

  90. Herzog C, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:572–86.

    PubMed  Google Scholar 

  91. Floege J, et al. Comprehensive clinical nephrology. Philadelphia: Saunders/Elsevier; 2010. p. 853–7. Chapter 71.

    Google Scholar 

  92. Gotloib L, et al. Peritoneal dialysis in refractory end-stage congestive heart failure: a challenge facing a no-win situation. Nephrol Dial Transplant. 2005;20 Suppl 7:vii32–6.

    PubMed  Google Scholar 

  93. Costanzo MR, et al. Early ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675–83.

    PubMed  CAS  Google Scholar 

  94. Forman MB, Virmani R, Robertson RM, Stone WJ. Mitral annular calcification in chronic renal failure. Chest. 1984;85(3):367.

    PubMed  CAS  Google Scholar 

  95. London GM, Pannier B, Marchais SJ, Guerin AP. Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol. 2000;11(4):778.

    PubMed  CAS  Google Scholar 

  96. Straumann E, Meyer B, Misteli M, Blumberg A, Jenzer HR. Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis. Br Heart J. 1992;67(3):236.

    PubMed  CAS  Google Scholar 

  97. Cosmi JE, Kort S, Tunick PA, Rosenzweig BP, Freedberg RS, Katz ES, Applebaum RM, Kronzon I. The risk of the development of aortic stenosis in patients with “benign” aortic valve thickening. Arch Intern Med. 2002;162(20):2345.

    PubMed  Google Scholar 

  98. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4 Suppl 3):S1.

    Google Scholar 

  99. Ureña P, Malergue MC, Goldfarb B, Prieur P, Guédon-Rapoud C, Pétrover M. Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors. Nephrologie. 1999;20(4):217.

    PubMed  Google Scholar 

  100. D’Cruz IA, Madu EC. Progression to calcific mitral stenosis in end-stage renal disease. Am J Kidney Dis. 1995;26(6):956.

    PubMed  Google Scholar 

  101. Lavie CJ, Hebert K, Cassidy M. Prevalence and severity of Doppler-detected valvular regurgitation and estimation of right-sided cardiac pressures in patients with normal two-dimensional echocardiograms. Chest. 1993;103(1):226.

    PubMed  CAS  Google Scholar 

  102. Stinebaugh J, Lavie CJ, Milani RV, Cassidy MM, Figueroa JE. Doppler echocardiographic assessment of valvular heart disease in patients requiring hemodialysis for end-stage renal disease. South Med J. 1995;88(1):65.

    PubMed  CAS  Google Scholar 

  103. Li Y, Muench A, McGregor DH, Wiegmann TB. Cerebral, myocardial and cutaneous ischemic necrosis associated with calcific emboli from aortic and mitral valve calcification in a patient with end-stage renal disease. Clin Nephrol. 2002;57(6):468.

    PubMed  CAS  Google Scholar 

  104. Renfrew R, Buselmeier TJ, Kjellstrand CM. Pericarditis and renal failure. Annu Rev Med. 1980;31:345–60.

    PubMed  CAS  Google Scholar 

  105. Rutsky EA, Rostand SG. Treatment of uremic pericarditis and pericardial effusion. Am J Kidney Dis. 1987;10:2–8.

    PubMed  CAS  Google Scholar 

  106. Compty CM, Cohen SL, Shapiro FL. Pericarditis in chronic uremia and its sequels. Ann Intern Med. 1971;75:173–83.

    Google Scholar 

  107. Barach AL. Pericarditis in chronic nephritis. Am J Med Sci. 1922;163:44–59.

    Google Scholar 

  108. Marini PV, Hull AR. Uremic pericarditis: a review of incidence and management. Kidney Int. 1975;2:163–6.

    Google Scholar 

  109. Alpert MA, Ravenscraft MD. Pericardial involvement in end-stage renal disease. Am J Med Sci. 2003;325(4):228.

    PubMed  Google Scholar 

  110. Gunukula SR, Spodick DH. Pericardial disease in renal patients. Semin Nephrol. 2001;21(1):52.

    PubMed  CAS  Google Scholar 

  111. Tseng JR, Lee MJ, Yen KC, Weng CH, Liang CC, Wang IK, Chang CT, Lin-Tan DT, Lin JL, Yen TH. Course and outcome of dialysis pericarditis in diabetic patients treated with maintenance hemodialysis. Kidney Blood Press Res. 2009;32(1):17.

    PubMed  Google Scholar 

  112. Ifudu O, Int J. Daily dialysis in hemodialysis patients with pericardial effusion: where are the data? Artif Organs. 1999;22(7):469.

    CAS  Google Scholar 

  113. Spodick DH. Acute cardiac tamponade. N Engl J Med. 2003;349(7):684.

    PubMed  Google Scholar 

  114. Soman SS, Sandberg KR, Borzak S, et al. The independent association of renal dysfunction and arrhythmias in critically ill patients. Chest. 2002;122:669.

    PubMed  Google Scholar 

  115. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Norpoth M, Metelli MR, Giovannini L, Tetta C, Palla R. C reactive protein in patients with chronic renal diseases. Ren Fail. 2001;23:551–62.

    PubMed  CAS  Google Scholar 

  116. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87–92.

    PubMed  CAS  Google Scholar 

  117. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006–10.

    PubMed  Google Scholar 

  118. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886–91.

    PubMed  CAS  Google Scholar 

  119. Green D, Roberts PR. Ventricular arrhythmias and sudden death in patients with chronic kidney disease. J Ren Care. 2010;36 Suppl 1:54–60.

    PubMed  Google Scholar 

  120. Korantzopoulos P, Liu T, Li L, Goudevenos JA, Li G. Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis. Europace. 2009;11(11):1469–75. Epub 2009 Oct 6.

    PubMed  Google Scholar 

  121. Wase A, Basit A, Nazir R, et al. Impact of chronic kidney disease upon survival among implantable cardioverter-defibrillator recipients. J Interv Card Electrophysiol. 2004;11:199.

    PubMed  Google Scholar 

  122. Dasgupta A, Montalvo J, Medendorp S, et al. Increased complication rates of cardiac rhythm management devices in ESRD patients. Am J Kidney Dis. 2007;49:656–63.

    PubMed  Google Scholar 

  123. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, Ojo A, Teal VL, Jensvold NG, Robinson NL, Dries DL, Bazzano L, Mohler ER, Wright JT, Feldman HI. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;159(6):1102–7.

    PubMed  Google Scholar 

  124. Horio T, Iwashima Y, Kamide K, Tokudome T, Yoshihara F, Nakamura S, Kawano Y. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens. 2010;28(8):1738–44.

    PubMed  CAS  Google Scholar 

  125. US Renal Data System. USRDS 2005 annual data report: atlas of end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005.

    Google Scholar 

  126. Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T, Nakayama K, Asayama K, Inoue R, Hashimoto J, Totsune K, Hoshi H, Ito S, Imai Y. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population-the Ohasama study. Nephrol Dial Transplant. 2007;22:1910–5.

    PubMed  Google Scholar 

  127. Abbott KC, Trespalacios FC, Taylor AJ, Agodoa LY. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol. 2003;4:1–10.

    PubMed  Google Scholar 

  128. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost. 2004;30:579–89.

    PubMed  CAS  Google Scholar 

  129. Tveit DP, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG, Abbott KC. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis. 2002;39:1011–7.

    PubMed  Google Scholar 

  130. Iseki K, Kinjo K, Kimura Y, Osawa A, Fukiyama K. Evidence for high risk of cerebral haemorrhage in chronic dialysis patients. Kidney Int. 1993;44:1086–90.

    PubMed  CAS  Google Scholar 

  131. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.

    PubMed  CAS  Google Scholar 

  132. Dahri K, Loewen P. The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost. 2007;98:980–7.

    PubMed  CAS  Google Scholar 

  133. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259–68. doi:10.2165/11318170-000000000-00000.

    PubMed  CAS  Google Scholar 

  134. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. 2002;61(4):1486.

    PubMed  Google Scholar 

  135. O’Hare A, Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 2001;12(12):2838.

    PubMed  Google Scholar 

  136. O’Hare AM, Hsu CY, Bacchetti P, Johansen KL. Peripheral vascular disease risk factors among patients undergoing hemodialysis. J Am Soc Nephrol. 2002;13(2):497.

    PubMed  Google Scholar 

  137. Rajagopalan S, Dellegrottaglie S, Furniss AL, Gillespie BW, Satayathum S, Lameire N, Saito A, Akiba T, Jadoul M, Ginsberg N, Keen M, Port FK, Mukherjee D, Saran R. Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation. 2006;114(18):1914.

    PubMed  Google Scholar 

  138. Leskinen Y, Salenius JP, Lehtimäki T, Huhtala H, Saha H. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis. 2002;40(3):472.

    PubMed  Google Scholar 

  139. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20(2):384.

    PubMed  CAS  Google Scholar 

  140. Boaz M, Weinstein T, Matas Z, Green, Smetana S. Peripheral vascular disease and serum phosphorus in hemodialysis: a nested case-control study. Clin Nephrol. 2005;63(2):98.

    PubMed  CAS  Google Scholar 

  141. Chan CT, Mardirossian S, Faratro R, Richardson RM. Improvement in lower-extremity peripheral arterial disease by nocturnal hemodialysis. Am J Kidney Dis. 2003;41(1):225.

    PubMed  Google Scholar 

  142. White JW, White RA, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, Halperin CJL, Hiratzka LF, Murphy WRC, Olin JW, Puschett JB, Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Jonathan. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation. 2006; 113(11):e463.

    Google Scholar 

  143. Koelemay MJ, Lijmer JG, Stoker J, Legemate DA, Bossuyt P. Magnetic resonance angiography for the evaluation of lower extremity arterial disease: a meta-analysis. JAMA. 2001;285(10):1338.

    PubMed  CAS  Google Scholar 

  144. Feringa HH, Karagiannis SE, Chonchol M, Vidakovic R, Noordzij PG, Elhendy A, van Domburg RT, Welten G, Schouten O, Bax JJ, Berl T, Poldermans D. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors. J Am Soc Nephrol. 2007;18(6):1872.

    PubMed  CAS  Google Scholar 

  145. Clagett GP, Sobel M, Jackson MR, Lip GY, Tangelder M, Verhaeghe R. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):609S.

    PubMed  CAS  Google Scholar 

  146. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329.

    Google Scholar 

  147. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness Jr DE, Bortey EB, Forbes WP. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159(17):2041.

    PubMed  CAS  Google Scholar 

  148. Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, Forbes WP. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27(2):267.

    PubMed  CAS  Google Scholar 

  149. Harrington EB, Harrington ME, Schanzer H, Haimov M. End-stage renal disease – is infrainguinal limb revascularization justified? J Vasc Surg. 1990;12(6):691.

    PubMed  CAS  Google Scholar 

  150. O’Hare AM, Sidawy AN, Feinglass J, Merine KM, Daley J, Khuri S, Henderson WG, Johansen KL. Influence of renal insufficiency on limb loss and mortality after initial lower extremity surgical revascularization. J Vasc Surg. 2004;39(4):709.

    PubMed  Google Scholar 

  151. O’Hare AM, Feinglass J, Reiber GE, Rodriguez RA, Daley J, Khuri S, Henderson WG, Johansen KL. Postoperative mortality after nontraumatic lower extremity amputation in patients with renal insufficiency. J Am Soc Nephrol. 2004;15(2):427.

    PubMed  Google Scholar 

  152. Karthikeyan V, Ananthasubramaniam K. Coronary risk assessment and management options in chronic kidney disease patients prior to kidney transplantation. Curr Cardiol Rev. 2009;5(3):177–86.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, St. John Providence Health System, 22101 Moross Rd., 2nd Floor, VEP Cath Lab, Detroit, MI, 48236, USA

    Firas Yazigi MD & Usman Hashmi MD

  2. Department of Nephrology, Johns Hopkins Hospital, 22101 Moross Rd., 2nd Floor, VEP Cath Lab, Detroit, MI, 48236, USA

    Henry Yuan MD

  3. Department of Internal Medicine, St. John Providence Health System, 22101 Moross Rd., 2nd Floor, VEP Cath Lab, Detroit, MI, 48236, USA

    Karthiek Narala MD

  4. Department of Providence Park Clinical Research, St. John Providence Health System, 47601 Grand River, B125, Novi, MI, 48374, USA

    Peter A. McCullough MD, MPH, FACC, FACP, FAHA

Authors
  1. Firas Yazigi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Usman Hashmi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henry Yuan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karthiek Narala MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter A. McCullough MD, MPH, FACC, FACP, FAHA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Firas Yazigi MD .

Editor information

Editors and Affiliations

  1. Division of Cardiology, Department of Medicine,, Stony Brook University, School of Medicine,, Stony Brook, USA

    Kathleen Stergiopoulos

  2. Division of Cardiology, Stony Brook University, Stony Brook, New York, USA

    David L. Brown

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Yazigi, F., Hashmi, U., Yuan, H., Narala, K., McCullough, P.A. (2014). Cardiovascular Issues and Renal Disease. In: Stergiopoulos, K., Brown, D. (eds) Evidence-Based Cardiology Consult. Springer, London. https://doi.org/10.1007/978-1-4471-4441-0_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4441-0_24

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4440-3

  • Online ISBN: 978-1-4471-4441-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation